Market Research Reports on Treating Refractory Hematological Malignancies

Market Research Report on Treating Refractory Hematological Malignancies provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.




To Find more :
Visit at : Market Research Reports on Treating Refractory Hematological Malignancies
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600

Treating Refractory Hematological Malignancies

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication - Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Table of Contents.

Executive Summary

2. Investment Drivers of The Select Companies Covered
3. Myelodysplastic syndrome (MDS)
3.1 Disease Overview
3.2 Unmet Need
3.3 Current Standard of Care
3.3.1 Supportive Care
3.3.2 Low-Intensity Therapy
3.3.3 High-Intensity Therapy
3.3.4 Recurrent/ Refractory or relapsed MDS
4. Acute Myelogenous Leukemia (AML)
4.1 Disease Overview
4.2 Current Standard of Care
4.2.1 AML pts younger than 60 years
a Induction Therapy
b Post-remission/ consolidation therapy
4.2.2 AML pts Older than 60 years

List Of Figures :

* Ambit Biosciences - MONOTHERAPY RESPONSE RATES (CRc) IN AML

* Ambit Biosciences - QUIZARITINIB - PhIIb COMPARABLE EFFICACY WITH LOWER DOSES 

* Ambit Biosciences - QTC PROLONGATION AT VARIOUS DOSES OF QUIZARTINIB 

* Ambit Biosciences - LONG TERM SURVIVORS IN PHASE 2 - TREATED WITH QUIZARTINIB 

* Ambit Biosciences - QUIZARTINIB MARKET OPPORTUNITY IN US IN AML 

* Ambit Biosciences - OVERALL SURVIVAL FOR AML PTS LESS THAN 60 YEAR OLD WITH FLT3 ITD MUTATION 

* Ambit Biosciences - PROPOSED PHIII TRIAL OF QUIZARTINIB

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTIME

* Onconova Therapeutics - ITT ANALYSIS: SURVIVAL DATA FOR REFRACTORY MDS PTS

* Onconova Therapeutics - BEST BONE MARROW (BM) RESPONSES AFTER RIG. IV

* Onconova Therapeutics - PHII TRIAL DESIGN - ONTARGET

* Onconova Therapeutics - PHIII TRIAL DESIGN - ONTRAC 

To order this report:

Treating Refractory Hematological Malignancie

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

Market Research Reports on Peptides in Oncology

Research Report on peptides in oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work.




To Find more :
Visit at : Market Research Reports on Peptides in Oncology
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600

Market research report on antibodies and peptides in oncology

Antibodies and Peptides in Oncology research report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work.





To Find more :

Visit at : Market research report on antibodies and peptides in oncology
Mail : support@researchonglobalmarkets.com
Call : +1 866 325 7446 / +91 22 4098 7600

Analytical Tool - Peptides in Oncology

"Analytical Tool- Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

Cancer Peptides: From First-in-Class to Best-in-Class?

Peptides in Oncology Drug Pipeline Update 2013

The Package Includes

* A progress analysis on current and emerging drugs

* Information on most companies active in peptide drug development in oncology

* Information on key industry related peptide drug projects in oncology

* Data from most important clinical trials

* Information on early developmental stage projects

* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

* Tracking cutting edge companies, therapies and new technologies

* Rapid identification of partners & competitors

* Laying down a comprehensive framework for further analysis of the field

* Producing presentations surrounding the development of peptide drugs in oncology

* Identifying emerging peptide cancer products & key areas of pharmaceutical R&D 

This software application is a searchable database reflects the most recent advances in the field of peptide drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeekers software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Peptides in Oncology

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED LINKS
http://www.researchonglobalmarkets.com

Analytical Tool - Antibodies and Peptides in Oncology

"Analytical Tool - Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available. 

Included in this advantageous package are four products already appreciated by many of our customers:

Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Cancer Peptides: From First-in-Class to Best-in-Class?

Antibodies in Oncology Drug Pipeline Update 2013

Peptides in Oncology Drug Pipeline Update 2013

The Package Includes

* A progress analysis on current and emerging drugs

* Information on most companies active in R&D

* Information on key industry related projects

* Data from most important clinical trials

* Information on early developmental stage project

* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

* Tracking cutting edge companies, therapies and new technologies

* Rapid identification of partners & competitors

* Laying down a comprehensive framework for further analysis of the field

* Producing presentations surrounding the development of antibody and peptide drugs in cancer

* Identifying emerging products & key areas of pharmaceutical R&D

This software application is a searchable database reflects the most recent advances in the field of antibody and peptide cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeekers software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Antibodies and Peptides in Oncology

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED LINKS
http://www.researchonglobalmarkets.com

Need for remote access interfaces in enterprises is driving the virtual desktop infrastructure market in the US

The virtual desktop infrastructure market in the US is forecasted to grow at a CAGR of 8.47% over 2014 to 2018. The market has been witnessing the growing adoption of cloud-based virtual desktop infrastructure solutions of late. However, the huge capital expenditure involved in network restructuring could pose a challenge to the future growth of this market.

Cloud computing and cloud-based applications and services are witnessing increased adoption from enterprises and end-users. With increasing bandwidth support being provided by the communication service providers, there has been a rapid increase in the access of enterprise data and applications by end-users through smartphones, tablets and other handheld devices.

Virtual desktop infrastructure images are being stored in the data centers and accessed over the cloud infrastructure which is decreasing the operational costs considerably. Further, with the cloud-based virtual desktop solutions finding increased adoption, there are many applications being supported on the cloud that are being accessed over the virtual desktop infrastructure solutions.

One of the major drivers of market growth in this area is the need for remote access interfaces for enterprise applications and data. With the adoption of virtual desktop infrastructure solutions, enterprises and end-users are able to easily access the applications and data from any location using their handheld devices.

However, one of the major challenges faced by the virtual desktop infrastructure market in the US is the concern for the huge capital expenditure required for restructuring the enterprise network to support the virtualized applications and services. This is because enterprises are required to procure the virtualization software and supporting applications that form the base for deploying the applications for their end-users.

For further insights, Virtual Desktop Infrastructure

About Research on Global Markets

Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports.

To know more about our services, connect with us: support@researchonglobalmarkets.com